Working... Menu

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00660959
Recruitment Status : Completed
First Posted : April 18, 2008
Last Update Posted : June 28, 2011
Cardiokine Biopharma, LLC
Information provided by:
CardioKine Inc.

Brief Summary:
The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIADH.

Condition or disease Intervention/treatment Phase
Hyponatremia With Normal Extracellular Fluid Volume Drug: lixivaptan Drug: placebo Phase 3

Detailed Description:
Phase I Phase II clinical trials have demonstrated that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with HF, liver cirrhosis with ascites (LCWA) and syndrome of inappropriate antidiuretic hormone (SIADH). Lixivaptan was previously evaluated in disease states characterized by hyponatremia with euvolemia (SIADH)and hyponatremia combined with fluid overload (HF, LCWA). Lixivaptan resulted in correction in hyponatremia together with a marked aquaresis in subject with volume overload. The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIDH.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 106 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia
Study Start Date : April 2008
Actual Primary Completion Date : June 2010

Arm Intervention/treatment
Experimental: Active Comparator
Drug: lixivaptan
oral capsule

Placebo Comparator: Placebo
Drug: placebo
oral capsule

Primary Outcome Measures :
  1. Average daily area under the curve (AUC) of change from baseline in serum sodium concentrations up to 72 hrs in lixivaptan treated subjects compared to placebo [ Time Frame: 60 days ]

Secondary Outcome Measures :
  1. Change from baseline in serum sodium on Day 30 [ Time Frame: 60 days ]
  2. Percentage of subjects achieving normalized serum sodium (Na+ ≥ 135 mEq/L) [ Time Frame: 60 days ]
  3. Time to first normalization of serum sodium (Na+≥135 mEq/L) [ Time Frame: 60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent
  • Men or women aged 18 or older
  • Diagnosis of euvolemic hyponatremia (120 ≤ Na+<130 mEq/L)
  • Hospitalized or willing to be admitted to a monitored setting for approximately the first 48 hours of treatment

Exclusion Criteria:

  • Pregnant or breast-feeding women, or women planning to become pregnant or to breastfeed
  • Symptomatic hyponatremia (e.g., lethargy, coma, seizures, changes in mental status attributable to hyponatremia)
  • Acute or transient hyponatremia (e.g., associated with head trauma or postoperative state)
  • Hyponatremia in hypovolemic states. Hypovolemic hyponatremia is defined as the presence of clinical evidence of extracellular fluid volume depletion
  • Hyponatremia as a result of any medication that can safely be withdrawn
  • Hyponatremia due to hypothyroidism or adrenal insufficiency
  • Diagnosis of psychogenic polydipsia
  • Receiving within 7 days of enrollment, other medication for treatment of hyponatremia specifically: demeclocycline, lithium carbonate, urea, or conivaptan
  • Use of radiotherapy and chemotherapy within 2 wks of randomization
  • Likely to require, or to receive IV saline for correction of symptomatic or asymptomatic severe hyponatremia during the course of the study
  • Supine systolic arterial blood pressure of ≤ 90 mmHg
  • Serum creatinine >3.0 mg/dL
  • History of uncontrolled type 2 diabetes mellitus
  • Severe pulmonary artery hypertension: patients whose condition is expected to deteriorate with sudden shifts in fluid volumes and cardiac filling pressures
  • Established diagnosis of New York Heart Association (NYHA) class III or IV heart failure
  • History of myocardial infarction, unstable angina or evidence of active ischemia within 30 days prior to screening
  • History of cerebral vascular accident (CVA) within 60 days prior to screening
  • Established diagnosis of nephrotic syndrome
  • Advanced liver disease or documented diagnosis of cirrhosis or alcoholic hepatitis
  • Urinary tract obstruction (benign prostatic hypertrophy [BPH] allowed if non-obstructive)
  • History of alcohol abuse or illicit drug use within the past 6 months
  • Terminally ill or moribund condition with little chance of short-term survival
  • Receiving vasopressin or its analogs for treatment of any condition
  • Known allergy to any vasopressin antagonist
  • Previous participation in a lixivaptan study
  • Recipient of any investigational treatment (drug or device) within 30 days prior to baseline visit
  • Unable to take oral medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00660959

  Hide Study Locations
Layout table for location information
United States, Alabama
Research Site 1
Mobile, Alabama, United States, 36617
United States, Arizona
PsyPharma Global
Phoenix, Arizona, United States, 85050
United States, California
Research Site
Los Angeles, California, United States, 90033
Research Site 1
Los Angeles, California, United States, 90073
Research Site 1
Roseville, California, United States, 95661
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
United States, District of Columbia
The George Washington University Medical Faculty Associates
Washington, District of Columbia, United States, 20037
United States, Florida
Healthcare Clinical Data, Inc
North Miami, Florida, United States, 33161
Cleveland Clinic Florida
Weston, Florida, United States, 33331
United States, Georgia
Research Site
Augusta, Georgia, United States, 30912
RTR Medical Group
Savannah, Georgia, United States, 31419
United States, Illinois
Research Site
Chicago, Illinois, United States, 60612
United States, Iowa
Research Site 1
Iowa City, Iowa, United States, 52242
United States, Kentucky
Four Rivers Clinical Research, Inc.
Paducah, Kentucky, United States, 42003
United States, Louisiana
Louisiana Research Associates, Inc.
New Orleans, Louisiana, United States, 70114
United States, Massachusetts
Research Site
Belmont, Massachusetts, United States, 02478
Research Site
Boston, Massachusetts, United States, 02135
Research Site
Boston, Massachusetts, United States, 02212
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Missouri
Research Site
Kansas City, Missouri, United States, 64128
United States, Nevada
Research Site 1
Las Vegas, Nevada, United States, 89106
United States, New York
Research Site 1
Albany, New York, United States, 12208
Erie County Medical Center
Buffalo, New York, United States, 14215
Research Site
New York, New York, United States, 10016
United States, North Carolina
Three Rivers Health and Rehabilitation
Windsor, North Carolina, United States, 27983
United States, Ohio
Atrium Medical Center
Middletown, Ohio, United States, 45005
Kettlie Joseph Daniels MD, Inc
Toledo, Ohio, United States, 43609
United States, Pennsylvania
Research Site 1
Camp Hill, Pennsylvania, United States, 17011
Research Site 1
Doylestown, Pennsylvania, United States, 18901
Research Site
Norristown, Pennsylvania, United States, 19401
Research Site 1
Philadelphia, Pennsylvania, United States, 19104
United States, Rhode Island
Research Site
Providence, Rhode Island, United States, 02903
United States, South Carolina
Research Site 1
Columbia, South Carolina, United States, 29209
United States, Texas
SunStar Geriatrics Healthcare
Georgetown, Texas, United States, 78626
Clinical Trial Network
Houston, Texas, United States, 77074
United States, Utah
Aspen Clinical Research
Orem, Utah, United States, 84058
United States, Virginia
The Glennan Center for Geriatrics and Gerontology
Norfolk, Virginia, United States, 23507
United States, Washington
Internal Medicine Northwest
Tacoma, Washington, United States, 98405
UZ Gasthulsberg
Leuven, Belgium, 3000
Centre Hospitalier de Tubize
Tubize, Belgium, 1480
Canada, Quebec
Research SIte
Greenfield Park, Quebec, Canada, J4V 2H1
Research Site 1
Montreal, Quebec, Canada, H1T 2M4
Research Site
Montreal, Quebec, Canada, H4J 1C5
Research Site
Berlin, Germany, 12200
Research Site
Berlin, Germany, 13353
Research Site
Dresden, Germany, 01307
Research Site
Giessen, Germany, 35392
Research Site
Hannover, Germany, 30167
Research Site
Heidelberg, Germany, 69120
Research SIte
Konstanz, Germany, 78464
Research Site
Magdeburg, Germany, 39120
Research Site
Munchen, Germany, 80336
Research Site
Wurzburg, Germany, 97080
Baby Memorial Hospital
Calicut, Kerala, India, 673004
Poona Hospital and Research Centre
Pune, Maharashtra, India, 411 030
Sir Ganga Ram Hospital
Old Rajinder Nagar, New Delhi, India, 110060
Deenanath Mengeshkar Hospital & Research Centre
Erandawane, Pune, India, 411 004
Fortis Escorts Hospital
Jaipur, Rajastan, India, 302017
Vidya Sagar Institute of Mental Health and Neurosciences
New Delhi, India, 110 065
Niepubliczny Zaklad Opieki Zdrowotney
Wilgury, Lodz, Poland, 90-302
Research Site
Bydgoszcz, Poland, 85-094
Research Site 1
Ciechanow, Poland, 06400
Research Site
Katowice, Poland, 40-027
Research Site 1
Lodz, Poland, 90-153
Research Site
Lublin, Poland, 20-954
Research Site 1
Podlaski, Poland, 08-300
Research Site 1
Warszawa, Poland, 02-097
Research Site
Warszawa, Poland, 02-097
Research Site 1
Warszawa, Poland, 02-507
Research Site 1
Warszawa, Poland
Samodzielny Publiczny Szpital Wojewodzki im. Papieza Jana Pawla II
Zamosc, Poland, 22-400
Sponsors and Collaborators
CardioKine Inc.
Cardiokine Biopharma, LLC

Layout table for additonal information
Responsible Party: Cardiokine, Inc Identifier: NCT00660959     History of Changes
Other Study ID Numbers: CK-LX3405
First Posted: April 18, 2008    Key Record Dates
Last Update Posted: June 28, 2011
Last Verified: November 2010

Keywords provided by CardioKine Inc.:
Serum Sodium
Fluid Overload
Vasopressin Antagonist

Additional relevant MeSH terms:
Layout table for MeSH terms
Water-Electrolyte Imbalance
Metabolic Diseases